CagriSema for Heart Health: What the Evidence Shows
What human and animal studies show about CagriSema for heart health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 1
- with an outcome for heart health, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for heart health, in our evidence file (PubMed search, 2 Oct 2026)
- Studies we summarised
- 2
- with an outcome for heart health
Evidence for heart health
Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Blood pressure | Systolic BP changed by -10.9 mm Hg with CagriSema versus -2.8 with placebo; diastolic BP by -5.4 versus -1.7 mm Hg at week 68. | Human RCTn = 3417 | Hypertension 2026, PMID 41328546 |
| Weight, waist, blood pressure and HbA1c | Versus placebo, CagriSema reduced body weight by a mean difference of -5.98% (-4.68 kg) and waist circumference by -10.91 cm, with reductions in systolic blood pressure and HbA1c. | Meta-analysisn = 5425 | Annals of medicine and surgery 2026, PMID 42583410 |
CagriSema and heart health are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What counts as heart disease
MedlinePlus calls heart disease a general term for many types of heart problems.[3]
Blood pressure data from the REDEFINE 1 trial
In a secondary analysis of REDEFINE 1, systolic blood pressure fell by 10.9 mm Hg with CagriSema against 2.8 mm Hg with placebo by week 68.[1]
More of the CagriSema group reached blood pressure targets than the placebo group, 63.0% against 32.0%.[1]
Among participants taking blood pressure medicines in the trial, 39.6% on CagriSema decreased or stopped treatment, against 18.8% on placebo.[1]
Registered cardiovascular outcomes
A phase 3 trial of CagriSema in people with heart and blood-vessel disease, registered as NCT05669755, lists time to first major adverse cardiovascular event as its primary measure.[4]
The REDEFINE 2 record registers change in systolic blood pressure over 68 weeks.[5]
The REDEFINE 1 record registers a systolic blood pressure comparison against placebo over 68 weeks.[6]
A lipid signal to know about
A meta-analysis of three trials found LDL cholesterol modestly higher with the combination than with semaglutide alone, by 0.29 mmol/L.[7]
Other peptides people research for heart health
All peptides for heart health, comparedCommon questions
Does CagriSema help with heart health?
The strongest study we summarise for heart health is human rct evidence, across 2 studies with an outcome for heart health. A trial result is not an approval; see the legal status.
Is CagriSema approved for heart health?
No. CagriSema is not FDA approved for any use, including heart health.
What is the best peptide for heart health?
There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.
Does CagriSema lower blood pressure?
In the REDEFINE 1 post hoc analysis the authors conclude CagriSema gave clinically relevant reductions in blood pressure across subgroups, including resistant hypertension.[1]
More on CagriSema
Sources
- 1CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
- 2Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
- 3Official web pageOfficial web page · web page
- 4The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 5Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 6Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 7Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes, obesity & metabolism · 2026PMID 41834765Accessed 2 Oct 2026
Found an error? Report a correction.